|
⚲
|
| Keyboard |
| Tybourne Capital Management HK Ltd
✚
|
|
|---|---|
| CRD # | 164723 |
| SEC # | 802-76945 |
| CIK # | 0001553936 |
| AUM | |
| Employees | |
| Fees | |
| Minimum | |
| Phone | 85239836800 |
| Address | Suites 818822, 8/F, Bank of America Tower Hong Kong, Hong Kong |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Taysha Gene Therapies Inc | 0.0 | ||
| Tocagen Inc | 0.0 | ||
| Alumis Inc | 0.0 | ||
| Zentalis Pharmaceuticals Inc | 0.0 | ||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | TSOF Co-Investment Fund 7 LP | 2026-03-30 | 11.0 M | |
| PE | TSOF Co-Investment Fund 6 LP | 2025-03-24 | 11.0 M | |
| HF | Westbourne Long Short Master Fund | 2024-03-28 | 83.0 M | |
| PE | TSOF Co-Investment Fund 5 LP | 2023-03-30 | ||
| PE | TSOF Co-Investment Fund 2 LP | 2022-03-28 | 4.5 M | |
| PE | TSOF Co-Investment Fund LP | [2022-03-28] | 9.1 M | |
| Filed 2021-02-25 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Tybourne Strategic Opportunities Fund II LP | [2022-03-28] | 102.0 M | 350.0 M |
| Filed 2022-05-03 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Tybourne Strategic Opportunties Fund LP | [2020-03-31] | 77.5 M | 346.0 M |
| Filed 2019-07-23 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| HF | Tybourne Long Opportunities Master Fund | [2014-03-31] | 649.4 M | 939.0 M |
| Filed 2024-11-18 (D/A) · Exemption 3(c)(7), 506(b) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Tybourne Equity Master Fund | [2012-07-18] | 1,670.5 M | 2,363.0 M |
| Filed 2021-11-17 (D/A) · Exemption 506(b), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Grant Jackson | Director | 175 | 39 | |
| Patrick Agemian | Director | 111 | 30 | |
| Gregory Link | Director | 85 | 19 | |
| James Walker | Director | 260 | 12 | |
| Viswanathan Krishnan | Director | 6 | 2 | |
| Tanvir Ghani | Director | 5 | 2 | |
| Tybourne Capital Management Limited | Promoter | 4 | 2 | |
| Tybourne Capital Management HK Limited | Promoter | 4 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001553936] | |
| 3 | [0001553936] | |
| 4 | [0001553936] | |
| SC 13D | [0001553936] | |
| SC 13G | [0001553936] |
| Firm Profile (Form ADV) | |
|---|---|
| Fund Types | Hedge Fund, Private Equity |
| LEI | 549300PW6DL740UUHC85 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
TPG Pace Beneficial Finance Corp TPGY
Class A Ordinary Shares
|
2021-12-30 | Sell | 4,817,252 | $9.81 | 47,257,242 |
|
TPG Pace Beneficial Finance Corp TPGY
Class A Ordinary Shares
|
2021-12-15 | Sell | 50,000 | $10.01 | 500,500 |
|
TPG Pace Beneficial Finance Corp TPGY
Class A Ordinary Shares
|
2021-12-14 | Sell | 40,050 | $10.07 | 403,304 |
|
TPG Pace Beneficial Finance Corp TPGY
Class A Ordinary Shares
|
2021-12-13 | Sell | 50,000 | $10.15 | 507,500 |
|
TPG Pace Beneficial Finance Corp TPGY
Class A Ordinary Shares
|
2021-03-19 | Buy | 146,836 | $19.59 | 2,876,517 |
|
TPG Pace Beneficial Finance Corp TPGY
Class A Ordinary Shares
|
2021-03-18 | Buy | 700 | $20.00 | 14,000 |
|
TPG Pace Beneficial Finance Corp TPGY
Class A Ordinary Shares
|
2021-03-18 | Buy | 273,910 | $19.47 | 5,333,028 |
|
TPG Pace Beneficial Finance Corp TPGY
Class A Ordinary Shares
|
2021-03-18 | Buy | 390 | $18.94 | 7,387 |
|
TPG Pace Beneficial Finance Corp TPGY
Class A Ordinary Shares
|
2021-03-17 | Buy | 32,037 | $18.77 | 601,334 |
|
TPG Pace Beneficial Finance Corp TPGY
Class A Ordinary Shares
|
2021-03-17 | Buy | 326,119 | $19.72 | 6,431,067 |
|
TPG Pace Beneficial Finance Corp TPGY
Class A Ordinary Shares
|
2021-03-16 | Buy | 195,000 | $19.87 | 3,874,650 |
|
Bicycle Therapeutics PLC BCYC
Series B2 Preferred Shares Warrants · derivative
|
2019-05-28 | Option exercise | 139,264 | $0.00 | |
|
Bicycle Therapeutics PLC BCYC
Ordinary Shares
|
2019-05-28 | Buy | 364,286 | $14.00 | 5,100,004 |
|
Bicycle Therapeutics PLC BCYC
Ordinary Shares
|
2019-05-28 | Option exercise | 139,264 | ||
|
Bicycle Therapeutics PLC BCYC
Ordinary Shares
|
2019-05-28 | Conversion | 1,454,411 | ||
|
Bicycle Therapeutics PLC BCYC
Series B2 Preferred Shares · derivative
|
2019-05-24 | Conversion | 1,454,411 | $0.00 | |
|
Boston Beer Co Inc SAM
Class A Common Stock, $.01 par value
|
2016-07-25 | Sell | 600 | $186.33 | 111,798 |